Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer

NCT02993094 is registered in ClinicalTrials.gov with Arbeitsgemeinschaft medikamentoese Tumortherapie as lead sponsor.

NCT NCT02993094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02993094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ixazomib (MLN9708) in Combination With Carboplatin in Pretreated Women With Advanced Triple Negative Breast Cancer
Lead sponsor
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase
Phase 1/2
Overall status
Terminated
Start date
November 21, 2016
Completion date
August 15, 2020
Enrollment
31 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

triple-negative breast cancer